Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: MONOGRAPH

IGF-1 DES

Plain-language summaryIntrigue 58 / 100

IGF-1 DES is a truncated form of IGF-1 missing the first three amino acids. The truncation reduces binding to IGF-binding proteins, producing a more potent local muscle effect. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

45/100

IGFBP-resistant IGF-1 fragment with real local potency advantage but thin human data and dated novelty

IGF-1 DES is the truncated cousin of native IGF-1: lose the first three residues (Gly-Pro-Glu) and you drop IGFBP binding substantially, which means the free fraction at target tissue goes up and local potency climbs roughly 10-fold over native IGF-1 in head-to-head in vitro models. That’s a real pharmacological distinction, and it’s why this form shows up specifically in muscle, bone, and neural tissue studies where local receptor activation is the question you’re actually asking.

What we like: the IGFBP angle is genuinely useful as a research probe. IGF binding proteins are a confounding layer in nearly every IGF-1 study, and DES lets you bypass that layer directly. If you’re interrogating IGF-1R signaling in tissue culture or local injection models, DES produces a cleaner readout than native IGF-1 without the IGFBP sink eating your signal. The receptor binding characteristics are documented across multiple lab groups, the functional potency difference is reproducible, and the mechanism is well-defined enough that you know what question you’re answering when you use it.

The problem is that this compound has been around since the late 1980s. The core biochemistry, characterized by Ballard and colleagues and expanded substantially by Sara and Hall in the early 1990s, is thoroughly mapped. The truncation strategy is elegant, but its a 35-year-old elegance. Compared to a mitochondrial-derived peptide or a novel triple incretin, DES sits firmly in the established-but-not-exciting column. Novelty here is historical, not current.

Versus IGF-1 LR3, the comparison is real and worth making: LR3 extends half-life to hours via the Arg3 modification, which suits systemic and sustained-release models. DES gives you a 20-30 minute half-life with higher peak local effect, which fits local-injection tissue models better. These are genuinely different tools for genuinely different questions, not just dose variants. That differentiation earns DES a niche. It doesn’t, however, make it dominant in the broader IGF research space where LR3 has the deeper translational literature.

What we dont love: human-specific data on the DES form is sparse. Most clinical IGF-1 work uses native IGF-1 or mecasermin. The case that DES specifically outperforms in a human research context is largely extrapolated from preclinical, and the short half-life doesn’t meaningfully reduce systemic exposure under repeated-dosing protocols. The same proliferative risk considerations that shadow native IGF-1 apply here in full.

Honestly, DES earns its place in an IGF toolkit as a mechanistic probe. It’s not a headline compound in 2026. Real pharmacological distinction, solid bench utility in local tissue models, but the novelty window on this one closed a generation ago.

Novelty

38

Mechanism promise

52

In-category differentiation

48

Evidence quality

42

Translational signal

38

Research bench value

58

Rationale IGF-1 DES is a well-characterized truncation with a genuine pharmacological distinction (IGFBP bypass, ~10x local potency) that earns real bench utility, but the core biochemistry was mapped in the late 1980s and human-specific DES evidence remains sparse relative to LR3 or native IGF-1. Scores reflect a solid but non-exciting tool compound with modest translational signal.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Truncated IGF-1 analog

A truncated form of IGF-1 missing the first three residues, with reduced IGFBP binding and increased local potency.

Abstract

IGF-1 DES (DES(1-3) IGF-1) is a truncated analog of human IGF-1 missing the first three N-terminal residues (Gly-Pro-Glu). The truncation reduces binding to IGF binding proteins (IGFBPs) and increases the free fraction of the peptide at target tissues, producing approximately 10-fold higher local potency than native IGF-1 at equivalent doses. The compound is sold as a research chemical. Plasma half-life is shorter than IGF-1 LR3 (approximately 20 to 30 minutes for IGF-1 DES vs hours for LR3) due to the absence of the Arg3 modification, but the increased local activity provides higher peak effects per dose. Investigational doses range widely; safety considerations parallel IGF-1 LR3 (chronic IGF-1 elevation effects on cancer risk and acromegalic features).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-088Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Coenzyme Q10 (Ubiquinol)

Plain-language summaryIntrigue 60 / 100

Coenzyme Q10 (ubiquinol when reduced) is an essential mitochondrial cofactor that participates in the electron transport chain. Levels decline with age and with statin use. Used as a heart-failure supplement and for energy. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Endogenous mitochondrial cofactor

An endogenous redox cofactor of the mitochondrial electron transport chain, declining with age and statin use, sold as a dietary supplement.

Abstract

Coenzyme Q10 (CoQ10, ubiquinone; CAS 303-98-0; molecular formula C59H90O4; molecular weight 863.34) is an endogenous redox cofactor essential for mitochondrial electron transport between Complex I/II and Complex III. The compound is synthesized from tyrosine and the mevalonate pathway; statin use reduces endogenous synthesis through HMG-CoA reductase inhibition (the same pathway used for cholesterol synthesis). Plasma and tissue CoQ10 decline with age. Supplementation has been studied for cardiovascular function (heart failure, hypertension), statin-associated muscle symptoms, and migraine prophylaxis. Bioavailability of the oxidized form (ubiquinone) is poor; the reduced form (ubiquinol) has 3- to 5-fold better bioavailability and is the preferred supplemental form for elderly subjects with reduced redox capacity. Doses are typically 100 to 400 mg per day of ubiquinol or higher of ubiquinone.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-120Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Vasopressin (DDAVP)

Plain-language summaryIntrigue 60 / 100

Vasopressin (antidiuretic hormone) and the synthetic analog DDAVP (desmopressin) regulate water retention by the kidneys. Used clinically for diabetes insipidus and bedwetting. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

45/100

Well-understood approved neuropeptide with solid clinical data but limited frontier research appeal

Look, vasopressin is one of those compounds where the clinical story is genuinely impressive and the research-frontier story is… not. It’s been known as antidiuretic hormone since the 1950s, the V1a/V1b/V2 receptor pharmacology is textbook-level established, and DDAVP has been FDA-approved for central diabetes insipidus since the late 1970s. The approved indications work, the mechanism is understood, and the hemostatic use in hemophilia A and von Willebrand disease type 1 represents real clinical value. None of that translates into a compelling research target for 2025.

The mechanism isnt bad on paper. V1b agonism in pituitary corticotrophs puts AVP squarely in the HPA axis conversation alongside CRH, and theres genuine academic interest in how the AVP/CRH synergy regulates ACTH release under stress. The social neuroscience angle, made famous by prairie vole studies on V1aR and pair bonding, spawned a decade of intranasal paradigms looking at trust, social memory, and aggression. We think that literature is interesting but also somewhat exhausted. The human signal for vasopressin’s social and cognitive effects has been inconsistent, and the intranasal delivery route introduces confounds that have complicated interpretation for years.

What we do like: DDAVP’s selectivity for V2 over V1 receptors makes it a reasonably clean probe for aquaporin-2 trafficking and collecting duct water transport physiology. If your lab is doing renal tubular biology or studying aquaporin regulation, DDAVP earns its place on the shelf. For V1b work on stress axis biology, native AVP is more appropriate than the synthetic analog. Those are real and defensible bench applications, just not frontier ones.

The cognitive enhancement use case, historically delivered at 1 to 2 IU intranasally, has a thin and unreplicated evidence base. The early Weingartner studies from the 1980s were never robustly confirmed. This isnt a developing story; it’s a closed one. The signal didnt survive scrutiny, and the more tractable approaches to neuropeptide-based cognition research have moved elsewhere.

Honestly, vasopressin scores where it scores because the compound is genuinely useful pharmacology in its approved lane and has bench probe value in specific subfields, but there’s no frontier angle that would make a serious investigator prioritize it over newer targets. High evidence quality and translational confidence for what it does; low novelty and differentiation for what it doesnt. That’s the tension that lands it here.

Novelty

22

Mechanism promise

33

In-category differentiation

35

Evidence quality

75

Translational signal

70

Research bench value

50

Rationale Vasopressin is a decades-old endogenous hormone with FDA-approved indications and a thoroughly mapped receptor pharmacology; its evidence quality and translational signal are high for approved uses, but novelty is low and the cognitive-enhancement research angle that made it culturally interesting in nootropic circles has largely failed to produce meaningful human signal, dragging differentiation and mechanism promise toward the middle of the scale.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous nonapeptide hormone

An endogenous nonapeptide hormone for water retention and vasoconstriction; the synthetic analog desmopressin (DDAVP) is FDA-approved for diabetes insipidus.

Abstract

Vasopressin (arginine vasopressin, AVP, antidiuretic hormone; CAS 113-79-1; molecular weight 1084.23) is an endogenous nonapeptide synthesized in the paraventricular and supraoptic nuclei. The synthetic analog desmopressin (DDAVP; deamino-D-arginine vasopressin) is FDA-approved for diabetes insipidus, primary nocturnal enuresis, hemophilia A, and von Willebrand disease type 1. Mechanism includes V1a (vascular smooth muscle), V1b (pituitary corticotrophs), and V2 (renal collecting duct) receptor agonism. Cognitive enhancement applications historically used intranasal vasopressin (1 to 2 IU intranasally) but the evidence base is weak and current clinical use is largely limited to the approved water-balance and hemostatic indications.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-136Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Doxepin (Low-Dose)

Plain-language summaryIntrigue 60 / 100

Doxepin is an old tricyclic antidepressant. At very low doses (3-6 mg, sold as Silenor) it works as an H1 antihistamine sleep aid without the antidepressant or anticholinergic effects of full doses. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

A 1969 TCA repurposed as a sleep drug; solid approval story, minimal research frontier appeal

Look, doxepin is a 1969 tricyclic antidepressant. The fact that someone noticed, decades later, that its H1 antagonism dominates at 3 to 6 mg and reformulated it as Silenor in 2010 is genuinely clever pharmacology. But clever is not the same as novel, and that distinction matters a lot for how we score this.

The mechanism insight here is dose-dependent receptor selectivity: at antidepressant doses (75 to 300 mg), doxepin hits muscarinic, alpha-1 adrenergic, and serotonergic receptors in ways that produce the classic TCA side-effect burden. Drop to the 3 to 6 mg range and what you’re left with is fairly selective H1 antagonism. That H1 blockade produces sleep continuity effects, meaning it targets maintenance insomnia, the 3am-wakeup phenotype, rather than onset. Thats a real and underappreciated clinical distinction. The plasma half-life of 15 hours is actually what makes it work; the drug is still present when early-morning sleep tends to fragment.

Here’s the thing, though: this story is 15 years old now. The Silenor approval trials (Krystal et al., Scharf et al., the 2010 package of phase 3 data) are well-replicated and well-designed. The evidence is solid. But the research conversation around sleep maintenance has largely moved on to orexin receptor antagonists. Suvorexant and lemborexant target the same clinical phenotype through a mechanism that most sleep researchers find considerably more interesting, and the dual-orexin-receptor angle has generated far more bench-level investigation over the last decade.

As a research probe, doxepin low-dose doesnt offer much that you couldnt get from a more selective H1 antagonist if H1 biology is what you’re actually studying. The 15-hour half-life makes washout kinetics awkward. Its not scheduled, which is a minor sourcing convenience relative to z-drugs or benzodiazepines, but that attribute alone doesnt make it an interesting bench target.

We think the honest placement here is: doxepin low-dose has good clinical evidence and a real approved indication, and it works. But “works for its indication” and “worth a serious investigator’s time in 2025” are different questions. The H1-for-sleep-maintenance story is mature and well-understood. The mechanism isnt revealing new biology. The differentiation from orexin antagonists cuts against it, not for it. If you’re building a sleep research program, this compound answers questions you mostly already know the answer to.

Novelty

22

Mechanism promise

25

In-category differentiation

38

Evidence quality

70

Translational signal

68

Research bench value

28

Rationale Doxepin low-dose scores as established-mature because the clinical evidence is real and replicated (FDA approval, multiple phase 3 RCTs for Silenor), but the mechanism is H1 antagonism, the literature is 15 years old on the low-dose reformulation angle, and orexin antagonists have largely superseded it as the more mechanistically interesting sleep-maintenance target. Low bench value as a probe compound drags the overall further.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tricyclic antidepressant / H1 antagonist

A tricyclic antidepressant FDA-approved at low doses (3 to 6 mg) as Silenor for sleep maintenance insomnia, exploiting selective H1 antihistamine activity at the low end of the dose range.

Abstract

Doxepin (Silenor at low doses; CAS 1668-19-5) is a tricyclic antidepressant approved at antidepressant doses (75 to 300 mg) since 1969 and reformulated at low doses (3 to 6 mg) by Somaxon and approved as Silenor in 2010 for sleep maintenance insomnia. At low doses, the compound shows selective H1 antihistamine activity; muscarinic, alpha-1 adrenergic, and serotonergic activities relevant at higher antidepressant doses are minimal. The H1-mediated sleep maintenance effect targets sleep continuity rather than sleep onset. Pharmacokinetics: plasma half-life 15 hours; CYP2D6 and CYP1A2 metabolism. Schedule status: prescription-only; not federally scheduled.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-152Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Magnesium Glycinate

Plain-language summaryIntrigue 50 / 100

Magnesium glycinate (also called magnesium bisglycinate) is magnesium bound to two glycine molecules. Glycine is also a calming amino acid, and the combination is well tolerated and absorbed without GI side effects. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundBasic mineral

23/100

A well-absorbed magnesium chelate that handles repletion well but offers no genuine research frontier

Look, magnesium glycinate is a better mousetrap for magnesium delivery, not a research frontier. The chelation with glycine solves a real problem: magnesium oxide, the dominant commercial form, has notoriously poor absorption (roughly 4-12% in clinical studies versus approximately 80% for the bisglycinate chelate), which means most people supplementing with oxide are largely supplementing with expensive stools. Glycinate fixes that. That’s genuinely useful, but it’s been understood for decades and doesn’t open a new research question.

The glycine component does add something worth noting. Glycine acts as a co-agonist at the NMDA receptor glycine site, and at doses needed to deliver 200-400 mg elemental magnesium you’re getting roughly 1-2 g glycine per serving, which overlaps with the sleep-promotion literature (Bannai et al., 2012, Frontiers in Neurology). The combination is biologically sensible. But “biologically sensible” isn’t “novel research territory.” Both components are well-characterized independently, and theres no unique pharmacological fingerprint to the chelate that you couldn’t dissect by studying magnesium and glycine separately in a cleaner design.

As a bench tool, magnesium glycinate is weak. Investigators studying NMDA glycine site pharmacology have far more specific probes. Investigators studying magnesium in the CNS would reach for L-threonate, which carries the documented CSF-targeting story out of the Slutsky lab at MIT and a genuinely differentiated mechanistic rationale. The bisglycinate form doesn’t give you precision or resolution you can’t get another way, and the literature treating it as a distinct research compound rather than a delivery vehicle is thin at best.

The differentiation story falls short too. It clearly beats oxide on GI tolerability and elemental yield. But magnesium taurate, malate, and L-threonate are credible comparators for different indications, and glycinate doesn’t dominate the class on any dimension beyond tolerability. That’s useful for compliance studies and population-level repletion trials. It’s not interesting for basic science.

What we’d say plainly: the evidence quality here is reasonable because the underlying magnesium and glycine literatures are large and mature. That’s not a point in favor of glycinate as a research target; it’s evidence the interesting questions in this space have mostly been answered. Repletion in deficient populations? Well-characterized. Novel mechanism, unexplored indication space, surprising biology? Absent. The score reflects a compound that does exactly what it promises, has been doing it for decades, and wont generate findings a bench scientist is going to find worth writing up.

Novelty

16

Mechanism promise

22

In-category differentiation

28

Evidence quality

32

Translational signal

22

Research bench value

15

Rationale Magnesium glycinate improves on oxide meaningfully via bioavailability and adds mild glycine pharmacology at the NMDA co-agonist site, but neither angle constitutes novel research territory; both components are fully characterized independently, there is no unique mechanistic fingerprint to the chelate, and the calculated score of 23 lands well below the generic-mineral ceiling without needing the cap to bind.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Magnesium-glycine chelate

A magnesium chelate with glycine, with superior bioavailability and minimal gastrointestinal effects compared with magnesium oxide.

Abstract

Magnesium glycinate (magnesium bisglycinate) is a chelated magnesium salt where magnesium is bound to two molecules of glycine. The compound has superior bioavailability compared with magnesium oxide (the most common but poorly absorbed form), with absorption rates approaching 80 percent in clinical studies versus 4 to 12 percent for oxide. Glycine has independent anxiolytic and sleep-promoting effects through NMDA glycine site activity. The combination produces a magnesium product with low gastrointestinal disturbance and additional glycine benefits at the dosing required for elemental magnesium repletion. Doses providing 200 to 400 mg elemental magnesium per day are typical.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-168Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
SAM-e (S-Adenosyl-L-Methionine)

Plain-language summaryIntrigue 65 / 100

SAM-e is the body’s principal methyl donor, used in countless biological reactions including neurotransmitter synthesis. As a supplement it has antidepressant effects with reasonable evidence and is used for liver disease and osteoarthritis. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

37/100

Decades-old methyl donor with real but modest clinical evidence, largely mined-out research territory

SAM-e has been a fixture in the depression and liver-disease literature since Italian investigators began publishing on it in the 1970s. Fifty years of literature is the first signal: this isn’t a discovery, it’s established biochemistry. The mechanism is real. SAM-e is the universal methyl donor, participating in over 100 cellular transmethylation reactions including DNA methylation, neurotransmitter precursor steps, and phosphatidylcholine synthesis via the PEMT pathway. What we like is that this actually matters biologically. What we dont like is that “biologically important” and “interesting current research target” arent the same thing.

The clinical story is genuinely better than most compounds in this library. Several European regulatory agencies approved SAM-e as a prescription medicine for depression and osteoarthritis, and that’s translational signal most research compounds will never achieve. Meta-analyses, including the Papakostas group’s work and the AHRQ systematic review, report antidepressant effect sizes broadly comparable to SSRIs in small-N comparisons (SMD roughly 0.3 to 0.5). The OA data is similarly positive at modest scale. There’s also a hepatoprotective literature, particularly for alcohol-associated liver disease and NAFLD, where methionine cycle disruption is mechanistically coherent and the evidence is credible.

Here’s the problem: none of this is generating new questions. The depression literature effectively peaked in the late 1990s and early 2000s. Researchers cite those trials in background sections now, not as frontiers to build on. The mechanism is too diffuse to work as a specific probe; methylating everything across a hundred pathways isn’t the same as answering a targeted biological question. If you want to perturb DNA methylation specifically, DNMT inhibitors like 5-azacytidine or decitabine give precision that SAM-e can’t. If you’re working on one-carbon metabolism, SAM-e tends to be an output you measure, not the primary intervention you deploy.

The most live contemporary angle is in liver disease and, to a lesser extent, the aging/epigenetics interface. Groups studying MAT1A to MAT2A synthetase isoform switching in ALD and NAFLD, including work from Mato and colleagues at CIC bioGUNE on hepatic methionine cycle dysregulation, are doing genuinely interesting things with SAM-e as a metabolic variable. Thats the narrowest slice where we’d still look for new signal. But it’s a contracting frontier, not an expanding one.

Honestly, SAM-e scores like what it is: an endogenous metabolite with fifty years of evidence, a mechanism that’s well-understood and diffuse, and no category where it’s clearly best-in-class today. The clinical evidence is better than many compounds at this score level, which keeps it from the floor, but there’s little here to build a new program around. Solid reference material for background reading, not a primary target.

Novelty

18

Mechanism promise

30

In-category differentiation

35

Evidence quality

52

Translational signal

58

Research bench value

38

Rationale SAM-e is foundational endogenous biochemistry with a genuine multi-decade clinical literature in depression and liver disease, but the mechanism is too diffuse to serve as a specific research probe, the literature peaked in the early 2000s, and there is no category where it is clearly best-in-class today; the raw calculation lands just under the foundational-metabolite structural ceiling.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous methyl donor

S-adenosyl-L-methionine, the principal methyl donor for cellular methylation reactions, supplemented for depression, osteoarthritis, and liver disease.

Abstract

SAM-e (S-adenosyl-L-methionine; CAS 29908-03-0; molecular formula C15H22N6O5S; molecular weight 398.44) is an endogenous nucleotide-amino acid conjugate that serves as the principal methyl donor for hundreds of cellular methylation reactions, including DNA methylation, neurotransmitter synthesis, phospholipid synthesis, and detoxification. Synthesis from methionine + ATP is rate-limited; supplementation provides methyl donor capacity. The compound is approved as a medicine in some European countries for depression and osteoarthritis; sold as a dietary supplement in the United States. Clinical evidence in depression is moderate (effect sizes comparable to standard antidepressants in small trials). Doses are typically 400 to 1600 mg per day in divided administrations. Can precipitate mania in bipolar patients; should not be combined with MAOIs.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-185Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Fluoxetine

Plain-language summaryIntrigue 70 / 100

Fluoxetine is the original Prozac, the drug that made SSRIs household vocabulary in the 1990s. It works by blocking the pump that pulls serotonin back into the nerve cell that released it, leaving more of the signal sitting in the gap between brain cells. Eli Lilly synthesized it in 1972; the FDA approved it in 1987. It is unusually long-lived in the body (the active leftover sticks around for over a week), which makes it forgiving of missed doses but also slow to clear if a doctor needs to switch medications. It also blocks the liver enzyme CYP2D6, which matters for drug interactions. Decades of trials in depression, OCD, bulimia, and anxiety have made it one of the most studied psychiatric drugs ever. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

Mature SSRI reference compound with exceptional evidence but near-zero novelty as a research target

Look, fluoxetine is one of the most consequential molecules in twentieth-century psychiatry. That’s exactly the problem. When a compound gets synthesized in 1972, approved in 1987, and prescribed to tens of millions of people before most of us owned a cell phone, there’s not a lot of frontier left to explore. The research literature on fluoxetine is not just mature, it’s geological. We’re not suggesting investigators ignore it. We are saying that putting it in a research library as a discovery target doesn’t make sense.

The mechanism story has some nuance worth acknowledging. Yes, fluoxetine is primarily a SERT inhibitor with a Ki around 1 nM, but the secondary 5-HT2C antagonism is pharmacologically real and does something that plain SERT blockade can’t fully explain. The disinhibition of noradrenergic and dopaminergic tone in the prefrontal cortex via that 5-HT2C route is the leading explanation for fluoxetine’s activating profile relative to other SSRIs. Thats not trivial. But its also not new. This was worked out in the 1990s and 2000s and the conversation has largely moved on to triple-reuptake inhibitors and psychoplastogens where the mechanism complexity is actually an open question.

Where fluoxetine earns its place is on the bench as a tool. It is the reference SSRI. If you’re validating a SERT binding assay, setting up an animal model of depression, or doing receptor selectivity work across the serotonergic system, fluoxetine is the positive control you reach for. The extraordinarily long half-life of the active norfluoxetine metabolite (seven to fifteen days) makes steady-state kinetics unusually predictable, which has genuine experimental utility. The CYP2D6 inhibition profile is also useful as a pharmacokinetic probe. These are real bench applications, just not frontier science.

The differentiation picture is honestly where fluoxetine falls hardest. Within the SSRI class, escitalopram and sertraline have largely displaced it clinically on tolerability grounds. The long half-life that makes PK work easier is also what makes titration and drug interactions more complicated. It’s not strictly worse than everything, it has real unique features, but calling it best-in-class on any dimension requires picking a dimension most clinicians and researchers have stopped caring about.

We think fluoxetine belongs in the library as a reference standard entry. It’s not a discovery target. It’s not interesting as a frontier compound. The score reflects a genuinely important, deeply understood molecule that a serious bench scientist would reach for as a control, not as a subject of primary investigation.

Novelty

10

Mechanism promise

22

In-category differentiation

28

Evidence quality

88

Translational signal

80

Research bench value

65

Rationale Fluoxetine scores high on evidence and translational signal because it is a fully approved antidepressant with decades of phase 3 data, but novelty is floor-level and the SERT-inhibition mechanism sits in the most saturated receptor class in psychopharmacology. Its research value today is almost entirely as a reference probe and positive control, not as a frontier investigation target.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective serotonin reuptake inhibitor

The first widely prescribed SSRI; a long-acting serotonergic antidepressant and a foundational reference compound for serotonin pharmacology.

Abstract

Fluoxetine ((R/S)-N-methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; CAS 54910-89-3; molecular formula C17H18F3NO; molecular weight 309.33) is a phenoxyphenylpropylamine SSRI synthesized at Eli Lilly in 1972 and approved by the FDA in 1987 as the first commercial SSRI under the trade name Prozac. The compound exhibits high affinity for the serotonin transporter (SERT, Ki approximately 1 nM) with comparatively weak activity at the norepinephrine transporter (Ki approximately 240 nM) and the dopamine transporter. Notable for an extraordinarily long elimination half-life (1 to 3 days for the parent compound, 7 to 15 days for the active norfluoxetine metabolite) which renders steady-state achievement slow but mitigates discontinuation syndrome. Pharmacologically distinguished from later SSRIs by 5-HT2C antagonism that contributes to noradrenergic and dopaminergic disinhibition in the prefrontal cortex, partially explaining the activating subjective profile. Hepatic metabolism is via CYP2D6 (primary) and CYP3A4 (secondary); the compound is itself a potent CYP2D6 inhibitor, producing clinically significant interactions with TCAs, antipsychotics, and beta-blockers. Used widely as a reference SSRI in serotonergic mechanism studies, animal models of depression, and as a positive control in receptor binding and reuptake assays.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-201Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Clozapine

Plain-language summaryIntrigue 78 / 100

Clozapine (Clozaril) is the most effective antipsychotic ever developed, and it has held that title since the 1980s without serious challenger. It was approved by the FDA in 1989 specifically for treatment-resistant schizophrenia and remains the only drug demonstrated to reduce suicidality in schizophrenia. The catch is severe: roughly one in 100 patients develops agranulocytosis, a potentially fatal collapse of white blood cell production, which is why every patient on clozapine in the United States must submit to weekly, then biweekly, then monthly blood draws indefinitely. Mechanistically it is the prototype atypical antipsychotic, with weak D2 blockade compensated by potent 5-HT2A blockade and a wide net of effects on histamine, muscarinic, and adrenergic receptors. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

57/100

Gold standard for treatment-resistant schizophrenia but low novelty and exhausted mechanism space limit research appeal

Look, clozapine is one of the most clinically important psychiatric compounds in modern medicine. The gold standard for treatment-resistant schizophrenia since the early 1990s, it consistently outperforms every other antipsychotic in TRS populations across decades of multi-center trials. That 1% agranulocytosis incidence is genuinely dangerous and the weekly CBC monitoring requirement through the first six months is a real burden on both patient and system, and still no other drug in the class has managed to displace it for TRS. That clinical track record is not marketing. Its real, its replicated, and its durable.

The receptor pharmacology is what put clozapine on the map as a research object. The weak D2 antagonism (Ki ~130 nM) paired with potent 5-HT2A antagonism (Ki ~16 nM), plus a broad off-target profile spanning D4, muscarinic M1-M5, H1, alpha-1, and multiple 5-HT subtypes, gave investigators the receptor-binding template that defined the entire atypical antipsychotic class. The M1 affinity (Ki ~7 nM) is particularly interesting for anyone studying muscarinic contributions to cognition or psychosis. The M4 partial agonism that produces paradoxical hypersalivation in an otherwise anticholinergic compound is one of the genuinely under-worked threads still worth pursuing.

Here’s the thing though: as a forward-looking research target, novelty is a real problem. This is a 1989 approved drug whose core mechanism has been studied exhaustively for 35 years. The atypical class it spawned has been dissected from every angle conceivable. The literature isnt sparse, its saturated. You can open any receptor pharmacology textbook and find clozapine used as the canonical example. Investigators reach for it precisely because the answers are known, not because theres something new to find. Thats the opposite of an underexplored compound.

What keeps clozapine relevant in a research library is its probe and comparator value. For anyone working on antipsychotic mechanism studies, its the reference everyone is implicitly measuring against. For investigators studying TRS biology, its essentially the only validated positive control. For labs interrogating D4 receptor function specifically, clozapines selectivity profile is still a useful tool despite the years. We think the M4 partial agonism angle and the CYP1A2 metabolism interactions (particularly in smokers, who dramatically accelerate clearance) remain underexplored relative to the compounds clinical importance.

Honestly, the positioning is this: outstanding evidence quality, strong translational signal, real bench probe value in the right context, but genuinely low novelty and a mechanism space that most investigators have already mapped thoroughly. For a lab focused on whats next in CNS pharmacology, clozapine is background knowledge. For a lab working specifically on treatment resistance mechanisms, comparative antipsychotic pharmacology, or muscarinic-dopamine crosstalk, it earns its place on the bench.

Novelty

20

Mechanism promise

40

In-category differentiation

65

Evidence quality

82

Translational signal

78

Research bench value

75

Rationale Clozapine earns strong marks on evidence quality, translational signal, and bench probe value given its canonical reference-compound role and unmatched TRS clinical record, but 1989 FDA approval, fully characterized multireceptor pharmacology, and a thoroughly saturated literature drag novelty and mechanism scores down sharply. No scheduling cap or structural category cap applies; the score reflects a genuinely important but mature compound with limited frontier value for forward-looking research programs.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Atypical antipsychotic / D4-D2 multireceptor antagonist

The prototype atypical antipsychotic; the gold standard for treatment-resistant schizophrenia, limited by agranulocytosis risk requiring weekly blood monitoring.

Abstract

Clozapine (8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine; CAS 5786-21-0; molecular formula C18H19ClN4; molecular weight 326.82) is a dibenzodiazepine atypical antipsychotic developed at Wander/Sandoz and approved by the FDA in 1989 under the trade name Clozaril. The compound is the prototype atypical antipsychotic, introducing the receptor profile that defines the class: weak D2 antagonism (Ki approximately 130 nM) combined with potent 5-HT2A antagonism (Ki approximately 16 nM), producing antipsychotic efficacy without the extrapyramidal symptoms typical of high-affinity D2 antagonists. Off-target activity is broad: H1, alpha-1, muscarinic M1-M5 (Ki approximately 7 nM at M1), 5-HT2C, 5-HT3, 5-HT6, 5-HT7 antagonism, contributing to sedation, weight gain, sialorrhea (paradoxical from M4 partial agonism), and orthostatic hypotension. The defining clinical feature is efficacy in treatment-resistant schizophrenia, where clozapine consistently outperforms other antipsychotics; the limitation is approximately 1 percent agranulocytosis incidence, requiring weekly CBC monitoring through the first 6 months and biweekly thereafter. Plasma half-life is 12 hours; metabolism is via CYP1A2 (primary), CYP3A4, CYP2D6. Used as the canonical atypical antipsychotic in mechanism studies and as the gold standard for treatment-resistant schizophrenia.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-232Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Buspirone

Plain-language summaryIntrigue 60 / 100

Buspirone (BuSpar) is the first non-benzodiazepine anxiolytic, approved by the FDA in 1986. Mechanistically it is unrelated to any sedative class: it is a partial agonist at the serotonin 5-HT1A receptor, with no GABA-A activity. That means it does not produce sedation, dependence, or withdrawal, and it has no recreational potential. The trade-off is that it works slowly (effects build over 2 to 4 weeks) and does not produce the fast acute relief patients expect from a benzodiazepine, which has limited its uptake despite its safety advantages. It is FDA-approved for generalized anxiety disorder and is widely used as add-on for SSRI-treated depression where some additional anxiolysis is needed. The active metabolite 1-PP is an alpha-2 antagonist contributing to the noradrenergic tone. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

44/100

Canonical 5-HT1A probe, mature anxiolytic with real evidence but thin novelty in 2026

Look, buspirone is a compound that was genuinely interesting in 1986. The first non-benzodiazepine anxiolytic approved by the FDA, it demonstrated that you could hit generalized anxiety disorder through 5-HT1A partial agonism rather than GABA-A potentiation, and that doing so meant no sedation, no tolerance, no physical dependence. For its era, that was a meaningful pharmacological statement. The mechanism story around autoreceptor desensitization, where the delayed anxiolytic onset (two to four weeks) reflects slow downregulation of presynaptic 5-HT1A somatodendritic autoreceptors, remains instructive for anyone studying serotonin system kinetics. The 1-PP metabolite’s alpha-2 antagonism adds a noradrenergic wrinkle that still gets cited in systems-level work.

The problem is that we’re rating research merit in 2026, not 1986. The 5-HT1A partial agonist mechanism is thoroughly mapped. There are no hidden pockets in this pharmacology waiting to be discovered by a bench investigator picking up buspirone today. Its Ki of approximately 21 nM and intrinsic activity around 35 percent are numbers that have appeared in textbooks for decades. Secondary D2 antagonism at roughly 100 nM is real but the clinical significance remains unclear after forty years of trying to pin it down. Thats not the profile of a compound that’s going to generate an interesting paper in 2026 unless you’re specifically using it as a reference probe.

And that’s honestly where buspirone still earns its keep. As the canonical 5-HT1A partial agonist, it is the go-to tool compound when you need to isolate this receptor’s contribution to a behavioral or neurochemical readout. Comparing full agonists, partial agonists, and antagonists at 5-HT1A? You’re reaching for buspirone. Disentangling 5-HT1A from 5-HT1B or 5-HT2A contributions in a circuit-level experiment? Buspirone is in the protocol. That probe value is real, particularly in translational anxiety models or serotonin-system interaction studies. It’s not a replacement for newer tools, but it’s not obsolete either.

What we don’t find compelling is the idea of prioritizing buspirone as a primary research target. Its evidence base is among the strongest in this library, multiple phase 3 RCTs, decades of replicated mechanism work, FDA approval since Reagan’s second term. But that evidence bulk is exactly the problem: the question has been answered. GAD pharmacology has moved on to SSRIs, SNRIs, and increasingly ketamine and psychoplastogen-adjacent compounds as the interesting frontier. Buspirone sits comfortably in the literature as a mature reference standard with modest differentiation from newer anxiolytics on actual clinical metrics. Score it accordingly.

Novelty

22

Mechanism promise

30

In-category differentiation

35

Evidence quality

72

Translational signal

65

Research bench value

60

Rationale Buspirone earns its score almost entirely from evidence quality, translational signal, and residual bench utility as the reference 5-HT1A partial agonist; novelty and mechanism promise are dragged down by 40 years of literature and a single-receptor story that the field has well characterized. No scheduling or category cap applies, but the raw calculation lands squarely in established-mature territory.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

5-HT1A partial agonist anxiolytic

An azapirone 5-HT1A partial agonist; a non-benzodiazepine anxiolytic without dependence or sedation.

Abstract

Buspirone (8-[4-(4-pyrimidin-2-yl-1-piperazinyl)butyl]-8-azaspiro[4.5]decane-7,9-dione; CAS 36505-84-7; molecular formula C21H31N5O2; molecular weight 385.50) is an azapirone 5-HT1A partial agonist developed at Bristol-Myers Squibb and approved by the FDA in 1986 under the trade name BuSpar. The compound is the first clinically approved non-benzodiazepine anxiolytic, distinguished by mechanism (5-HT1A partial agonism rather than GABA-A potentiation), tolerance/dependence profile (none), and absence of sedation. 5-HT1A affinity is approximately 21 nM (intrinsic activity approximately 35 percent); secondary D2 antagonism (Ki approximately 100 nM) is of unclear clinical significance. The active metabolite 1-(2-pyrimidinyl)piperazine (1-PP) is an alpha-2 adrenergic antagonist contributing to noradrenergic effects. Onset of anxiolytic effect is delayed (2 to 4 weeks), reflecting the time course of 5-HT1A autoreceptor desensitization. Plasma half-life is 2 to 3 hours; metabolism is extensive via CYP3A4 with significant first-pass effect (oral bioavailability approximately 4 percent). Approved for generalized anxiety disorder. Used as the canonical 5-HT1A partial agonist in mechanism studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-248Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Cardarine (GW-501516)

Our opinion on this compoundNiche research probe

43/100

Canonical PPAR-delta probe with real bench utility and a decisively dead translational path

Look, GW-501516 occupies a genuinely unusual position in the research compound landscape. It’s not a novel discovery and it’s not a failed hypothesis. It’s a tool with real utility that was abandoned for safety reasons, and understanding that distinction matters for how you think about it.

The mechanism is legitimate. PPAR-delta activation in skeletal muscle drives fatty acid oxidation and mitochondrial biogenesis through the PGC-1alpha axis. GSK’s phase 2 work in dyslipidemia showed real changes: HDL going up, triglycerides coming down. The biology is coherent and the compound does what it’s supposed to do. Thats actually part of what makes the carcinogenicity story so uncomfortable: this isn’t a failed mechanism, it’s a working mechanism in a compound that accelerates tumor growth at the same time.

The 2007 carcinogenicity data is what ended the GSK program. Long-term studies in both rats and mice showed dose-dependent tumor formation across multiple organ systems at every dose level tested. Not a marginal finding in one tissue at high dose: multiple tissues, multiple species, dose-response fully intact. WADA banned it in 2009. The recreational community largely ignored both of these facts, which is its own kind of signal about how people evaluate uncomfortable data when a compound does something they want it to do.

Here’s what keeps GW-501516 on the map for serious researchers: it remains the most well-characterized PPAR-delta agonist available for academic metabolic research. If you want to study PPAR-delta biology, fat oxidation pathways, mitochondrial biogenesis signaling, or the relationship between endurance capacity and substrate utilization, GW-501516 is still the reference compound. There arent many clean alternatives with comparable depth of characterization. That’s real bench value, and we give it credit for that specifically.

What it doesn’t have is a translational future. The clinical development program is dead and is not coming back. Any research program using this compound has to be oriented toward mechanistic probe work, not toward a clinical endpoint. That’s a legitimate scientific purpose, and there are genuine questions about PPAR-delta biology worth pursuing. But the constrained scope is real, and it shows up in the score.

We think the honest framing is: useful tool, dangerous compound, dead translational path. For a researcher working on PPAR-delta biology, muscle metabolism, or mitochondrial signaling in skeletal tissue, this compound is worth understanding. For anyone thinking about a translational arc or a human-facing program, there is nothing here to build toward. The score reflects that balance: a solid niche probe with no credible exit toward clinical relevance.

Novelty

30

Mechanism promise

38

In-category differentiation

58

Evidence quality

50

Translational signal

30

Research bench value

62

Rationale GW-501516 earns its differentiation and bench-value scores as the reference PPAR-delta agonist with genuine phase 2 lipid data, but tanks on translational signal and novelty because the clinical program is permanently closed by dose-dependent multi-organ carcinogenicity across both rodent species; no structural cap applies because the mechanism is intact and validated, only the safety profile is fatal.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

PPAR-delta agonist (not a SARM)

A PPAR-delta agonist developed for dyslipidemia; widely used recreationally as an endurance enhancer despite cancer findings in long-term rodent studies.

Abstract

Cardarine (GW-501516, Endurobol; CAS 317318-70-0; molecular formula C21H18F3NO3S2; molecular weight 453.50) is a peroxisome proliferator-activated receptor delta (PPAR-delta) agonist developed at GlaxoSmithKline for dyslipidemia. The compound is not a SARM; it is grouped with SARMs in popular discourse owing to similar recreational use patterns. PPAR-delta activation in skeletal muscle increases fatty acid oxidation, mitochondrial biogenesis, and endurance capacity. Phase 2 trials in dyslipidemia demonstrated favorable lipid profile changes (HDL increase, triglyceride decrease). Development was halted by GSK in 2007 after long-term carcinogenicity studies in rats and mice showed dose-dependent tumor formation in multiple organs at all dose levels tested. The compound retains research utility as the canonical PPAR-delta agonist for academic metabolic research and is widely used recreationally despite the carcinogenicity signal; banned by WADA. Plasma half-life is approximately 24 hours.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-265Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 34 35 36 37 38 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.